OTC : TCHBF

Tecan Group AG

$252.06 USD

$0 (0.0%)

Volume
1
Average Volume
16
Market Capitalization
$3.19B
P/E Ratio
-22.32
Dividend Yield
1.54%
Price Target
Year High
$252.06
Year Low
$155.25
Day High
—
Day Low
—
Payout Ratio
-$0.34
Current Ratio
$2.46
Company Overview

OTC

Monica Manotas

Medical - Diagnostics & Research

Healthcare

TCHBF

3244

CH

USD

https://www.tecan.com

41 44 922 88 88

N/A

N/A

Liquidity Metrics

0.19

2.46

1.73

0.61

-0.34

Sales & Valuation

$882.9M

2.80

2.15

24.05

8.10

Profitability

-$8.74

-$110.71M

-12.54%

-11.47%

-9.09%

-6.52%

P/E Metrics

-22.32

0.08

0.08

Analyst Price Target & Rating

Sell

2/5

0 Analysts

%

Financial Health Scores

5.11

4/9

$422.99M

$1.7B

$546.6M

$126.24M

Key Metrics (TTM)

$2.51B

2.85

25.22

2.46

-9.09%

3.13%

-4.48%

4.16%

186 days

Company Executives
Name Title
Andreas Wilhelm EVice President of Legal, Qua. & Regu. Affairs, Gen. Cou., Sec. of the Board of Dir. & Mem. of Mgmt Board
Camila Japur Chief Financial Officer
Ulrich Kanter Executive Vice President, Global Head of Operations & IT and Member of Management Board
Carsten Boegh Chief Technology Officer, Executive Vice President, Head Research & Development & Member of the Management Board
Erik Norström Head of Corporate Development, Executive Vice President & Member of Management Board
Martin Brandle Senior Vice President of Corporate Communications & Investor Relations
Wolfgang Deuringer President of Sales International
Ingrid Purgstaller Chief People Officer & Member of the Management Board
Monica Manotas Chief Executive Officer, Interim Head of the Partnering Business division & Member of Management Board
Mukta Acharya EVP, Head of the Life Sciences Business Division & Member of the Management Board
Sarah Vowles Director Sustainability & Corporate Communications
Poll Results

No votes yet today — be the first to share your view!

About Tecan Group AG (OTC:TCHBF) Stock

Tecan Group AG is a specialized provider of advanced laboratory instruments and comprehensive solutions, serving a diverse clientele that includes pharmaceutical and biotechnology firms, academic research institutions, and forensic and diagnostic testing facilities. The company operates through two primary divisions: the Life Sciences Business and the Partnering Business. Its extensive product portfolio features automated liquid handling systems, microplate readers and washers, various consumables, next-generation sequencing (NGS) reagents, immunoassays, microbody products, and specialized software. Noteworthy solutions include Tecan Laberwax, an innovative automation platform, and Resolvex, an intelligent sample preparation system crucial for applications in genomics, synthetic biology, d ... rug discovery, analytical chemistry, cell biology, protein science, numerous applied markets, and ELISA solutions. Tecan also functions as a key supplier to other laboratory instrument manufacturers, providing essential components like high-precision pumps, valves, robotic arms, and development software, vital for life science research, diagnostics, and other sectors. Further offerings include Synergence, a versatile platform for automation, and the widely recognized Freedom EVO and Fluent instrument series. Established in 1980 and headquartered in Männedorf, Switzerland, Tecan Group AG maintains a significant global presence, with operations spanning Switzerland, various other European nations, North America, Asia, and other international markets.

Tecan Accelerates Data-Driven Lab Journey With Agentic AI Developments Powered by NVIDIA

2026-06-24 05:06:00

MÄNNEDORF, Switzerland--(BUSINESS WIRE)--Tecan (SIX Swiss Exchange: TECN), a global provider of laboratory automation and solutions, today announced the integration of Agentic AI capabilities into its lab analytics platform Introspect, leveraging NVIDIA BioNeMo Agent Toolkit. The NVIDIA BioNeMo Agent Toolkit enables AI agents to access scientific AI capabilities directly within the Introspect platform, helping laboratories to optimize operations. Agentic AI will allow laboratories to move beyon.

Frequently Asked Questions

What is the current Tecan Group AG (TCHBF) stock price?

Tecan Group AG(OTC:TCHBF) stock price is $252.06 in the last trading session. During the trading session, TCHBF stock reached the peak price of $252.06 while $155.25 was the lowest point it dropped to. The percentage change in TCHBF stock occurred in the recent session was 0.0% while the dollar amount for the price change in TCHBF stock was $0.

TCHBF's industry and sector of operation?

The OTC listed TCHBF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of TCHBF?

Andreas Wilhelm | EVice President of Legal, Qua. & Regu. Affairs, Gen. Cou., Sec. of the Board of Dir. & Mem. of Mgmt Board
Camila Japur | Chief Financial Officer
Ulrich Kanter | Executive Vice President, Global Head of Operations & IT and Member of Management Board
Carsten Boegh | Chief Technology Officer, Executive Vice President, Head Research & Development & Member of the Management Board
Erik Norström | Head of Corporate Development, Executive Vice President & Member of Management Board

How many employees does TCHBF have?

Number of TCHBF employees currently stands at 3244. TCHBF operates from Seestrasse 103, Männedorf, ZH 8708, CH.

Link for TCHBF official website?

Official Website of TCHBF is: https://www.tecan.com

How do I contact TCHBF?

TCHBF could be contacted at phone #41 44 922 88 88 and can also be accessed through its website. TCHBF operates from Seestrasse 103, Männedorf, ZH 8708, CH.

How many shares of TCHBF are traded daily?

The average number of TCHBF shares traded daily for last 3 months was 16.

What is the market cap of TCHBF currently?

The market value of TCHBF currently stands at $3.19B with its latest stock price at $252.06